Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | **[[Esophageal adenocarcinoma]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
| + | *[[Non-small cell lung cancer, EGFR-mutated]] | ||
| + | *[[Thyroid cancer, differentiated]] | ||
==Also known as== | ==Also known as== | ||
| Line 22: | Line 25: | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Thyroid cancer, differentiated medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Revision as of 01:19, 1 May 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
- Esophageal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Non-small cell lung cancer, EGFR-mutated
- Thyroid cancer, differentiated
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan